{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:56Z","timestamp":1790810096021,"version":"4.1.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Up to 30% of colorectal, endometrial and gastric cancers have a deficiency in mismatch repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients with Lynch Syndrome who inherit an inactive MMR allele have an up to 80% risk for developing a mismatch repair deficient (MMRd) cancer. Due to an inability to repair DNA, MMRd tumors present with genomic instability in microsatellite regions (MS). Tumors with high MS instability (MSI-H) are characterized by an increased frequency of insertion\/deletions (indels) that can encode novel neoantigens if they occur in coding regions. The high tumor antigen burden for MMRd cancers is accompanied by an inflamed tumor microenvironment (TME) that contributes to the clinical effectiveness of anti-PD-1 therapy in this patient population. However, between 40 and 70% of MMRd cancer patients do not respond to treatment with PD-1 blockade, suggesting that tumor-intrinsic and -extrinsic resistance mechanisms may affect the success of checkpoint blockade. Immune evasion mechanisms that occur during early tumorigenesis and persist through cancer development may provide a window into resistance pathways that limit the effectiveness of anti-PD-1 therapy. Here, we review the mechanisms of immune escape in MMRd tumors during development and checkpoint blockade treatment, including T cell dysregulation and myeloid cell-mediated immunosuppression in the TME. Finally, we discuss the development of new therapeutic approaches to tackle resistance in MMRd tumors, including cancer vaccines, therapies targeting immunosuppressive myeloid programs, and immune checkpoint combination strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1210164","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T05:58:40Z","timestamp":1688968720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":94,"title":["Immune escape and resistance to immunotherapy in mismatch repair deficient tumors"],"prefix":"10.3389","volume":"14","author":[{"given":"Guillaume","family":"Mestrallet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu Cimen","family":"Bozkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cr.2007.115","article-title":"Mechanisms and functions of DNA mismatch repair","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res"},{"key":"B2","article-title":"Relationship between MLH-1, MSH-2, PMS-2,MSH-6 expression and clinicopathological features in colorectal cancer","volume":"8","author":"Karahan","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM200001133420201","article-title":"Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer","volume":"342","author":"Gryfe","year":"2000","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70499-3","article-title":"Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features","volume":"116","author":"Yamamoto","year":"1999","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-015-0331-y","article-title":"Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network","volume":"16","author":"Sunakawa","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.03.002","article-title":"Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis","volume":"88","author":"Diaz-Padilla","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cncr.21560","article-title":"Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma","volume":"106","author":"Broaddus","year":"2006","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29046","article-title":"Polymerase \u03b5 (POLE) mutations in endometrial cancer: clinical outcomes and implications for lynch syndrome testing","volume":"121","author":"Billingsley","year":"2015","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.12.003","article-title":"Mismatch repair deficiency in ovarian cancer \u2013 molecular characteristics and clinical implications","volume":"132","author":"Xiao","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2906-9","article-title":"Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches","volume":"75","author":"Ratti","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.828","article-title":"Frequency of mismatch repair Deficiency\/High microsatellite instability and its role as a predictive biomarker of response to immune checkpoint inhibitors in gynecologic cancers","volume":"54","author":"Noh","year":"2022","journal-title":"Cancer Res Treat Off J Korean Cancer Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21169","article-title":"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers","volume":"8","author":"Salem","year":"2017","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001432","article-title":"Mismatch repair deficiency in ovarian carcinoma: frequency, causes, and consequences","volume":"44","author":"Leskela","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1038\/s41467-021-27620-x","article-title":"Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response","volume":"12","author":"Yen","year":"2021","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.8484121","article-title":"Clues to the pathogenesis of familial colorectal cancer","volume":"260","author":"Aaltonen","year":"1993","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/363558a0","article-title":"Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis","volume":"363","author":"Ionov","year":"1993","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.8484120","article-title":"Genetic mapping of a locus predisposing to human colorectal cancer","volume":"260","author":"Peltom\u00e4ki","year":"1993","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.8484122","article-title":"Microsatellite instability in cancer of the proximal colon","volume":"260","author":"Thibodeau","year":"1993","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20502","article-title":"A new variant database for mismatch repair genes associated with lynch syndrome","volume":"28","author":"Woods","year":"2007","journal-title":"Hum Mutat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.757804","article-title":"Lynch syndrome and MSI-h cancers: from mechanisms to \u201cOff-The-Shelf\u201d cancer vaccines","volume":"12","author":"Roudko","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","article-title":"Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors","volume":"183","author":"Roudko","year":"2020","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41467-022-29920-2","article-title":"Mutational landscape of normal epithelial cells in lynch syndrome patients","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site [[\/amp]]mdash; when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795048","article-title":"The cGAS-STING pathway: a promising immunotherapy target","volume":"12","author":"Ou","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair\u2013Deficient\/Microsatellite instability\u2013high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_349557","article-title":"Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite Instability\/Mismatch repair deficiency in 2022","volume":"42","author":"Andr\u00e9","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126288","article-title":"Anti-PD1\/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations","volume":"22","author":"Dantoing","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013Small-Cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS266","article-title":"A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-h)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): checkmate 8HW","volume":"38","author":"Abdullaev","year":"2020","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003414","article-title":"Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers","volume":"9","author":"Kim","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1482","article-title":"Immune profiling of premalignant lesions in patients with lynch syndrome","volume":"4","author":"Chang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.11.029","article-title":"The different immune profiles of normal colonic mucosa in cancer-free lynch syndrome carriers and lynch syndrome colorectal cancer patients","volume":"162","author":"Bohaumilitzky","year":"2021","journal-title":"Gastroenterology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-020-00161-w","article-title":"Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies lynch syndrome patients","volume":"19","author":"Brand","year":"2020","journal-title":"Fam Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01337-5","article-title":"Divergent clonal differentiation trajectories of T cell exhaustion","volume":"23","author":"Daniel","year":"2022","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J Exp Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","first-page":"eaay1863","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4574","article-title":"Myeloid cell-associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.matbio.2015.04.004","article-title":"Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature","author":"Deryugina","year":"2015","journal-title":"Matrix Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21037\/atm-20-4843","article-title":"Cancer-associated fibroblasts promote the migration and invasion of gastric cancer cells via activating IL-17a\/JAK2\/STAT3 signaling","volume":"8","author":"Zhang","year":"2020","journal-title":"Ann Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-021-01581-6","article-title":"Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency","volume":"28","author":"Das","year":"2022","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34025","article-title":"A phase 2 evaluation of pembrolizumab for recurrent lynch-like versus sporadic endometrial cancers with microsatellite instability","volume":"28","author":"Bellone","year":"2021","journal-title":"Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"CD","DOI":"10.1158\/2159-8290.CD-22-0686","article-title":"Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma","volume":"13","author":"Chow","year":"2022","journal-title":"Cancer Discov"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113374","article-title":"Tumor MHC expression guides first-line immunotherapy selection in melanoma","volume":"12","author":"Shklovskaya","year":"2020","journal-title":"Cancers"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discovery"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00321","article-title":"Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high","volume":"3","author":"Middha","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0987","article-title":"CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors","volume":"11","author":"Germano","year":"2021","journal-title":"Cancer Discov"},{"key":"B73","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00930","article-title":"Immune cytolytic activity as an indicator of immune checkpoint inhibitors treatment for prostate cancer","volume":"8","author":"Gao","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B75","article-title":"Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer","volume":"11","author":"Oshi","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9060243","article-title":"Immune cytolytic activity for comprehensive insights of the immune landscape in endometrial carcinoma","volume":"2022","author":"Chen","year":"2022","journal-title":"J Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6506-6","article-title":"Cytolytic activity score to assess anticancer immunity in colorectal cancer","volume":"25","author":"Narayanan","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005443","article-title":"Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer","volume":"10","author":"Palomero","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.12.015","article-title":"Molecular approaches for classifying endometrial carcinoma","volume":"145","author":"Piulats","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4472","article-title":"Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic","volume":"91","author":"Phillips","year":"2004","journal-title":"Br J Surg"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033604","article-title":"Biomarkers for response to immune checkpoint blockade","volume":"4","author":"Ganesan","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","article-title":"Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy","volume":"12","author":"Somasundaram","year":"2021","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1504729","article-title":"Human mast cells promote colon cancer growth via bidirectional crosstalk: studies in 2D and 3D coculture models","volume":"7","author":"Yu","year":"2018","journal-title":"Oncoimmunology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B86","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01262-7","article-title":"Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy","volume":"23","author":"Boukhaled","year":"2022","journal-title":"Nat Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"0041","DOI":"10.1158\/1078-0432.CCR-22-0041","article-title":"Transcriptomic profiling of MSI-H\/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy","volume":"28","author":"Chida","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112638","article-title":"Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers","volume":"13","author":"Amodio","year":"2021","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980709","article-title":"Strategies to overcome DC dysregulation in the tumor microenvironment","volume":"13","author":"Mestrallet","year":"2022","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700407","article-title":"Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity","volume":"200","author":"Dixon","year":"2018","journal-title":"J Immunol Baltim Md 1950"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.573405","article-title":"Effective anti-tumor response by TIGIT blockade associated with Fc\u03b3R engagement and myeloid cell activation","volume":"11","author":"Han","year":"2020","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005059","article-title":"Overcoming resistance to \u03b1PD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of \u03b1CTLA-4 and \u03b1PD-1 blockers","volume":"10","author":"Nebot-Bral","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"B103","first-page":"49","article-title":"Chapter two - unexplored horizons of cDC1 in immunity and tolerance","volume-title":"Advances in immunology","author":"Balan","year":"2020"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061438","article-title":"Human keratinocytes inhibit CD4+ T-cell proliferation through TGFB1 secretion and surface expression of HLA-G1 and PD-L1 immune checkpoints","volume":"10","author":"Mestrallet","year":"2021","journal-title":"Cells"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.786859","article-title":"Immunosuppressive properties of epidermal keratinocytes differ according to their immaturity status","volume":"13","author":"Mestrallet","year":"2022","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772516","article-title":"Skin immunity and tolerance: focus on epidermal keratinocytes expressing HLA-G","volume":"12","author":"Mestrallet","year":"2021","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.696","article-title":"Combined analysis of HLA class I, HLA-e and HLA-G predicts prognosis in colon cancer patients","volume":"110","author":"Zeestraten","year":"2014","journal-title":"Br J Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144000","article-title":"HLA-G 3\u2019UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment","volume":"10","author":"Garziera","year":"2015","journal-title":"PloS One"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2011.01716.x","article-title":"Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer","volume":"78","author":"Cao","year":"2011","journal-title":"Tissue Antigens"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111929","article-title":"Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-g+ cancer cells and SPP1+ macrophages in colorectal cancer","volume":"42","author":"Ozato","year":"2023","journal-title":"Cell Rep"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-022-05105-1","article-title":"MYB orchestrates T cell exhaustion and response to checkpoint inhibition","volume":"609","author":"Tsui","year":"2022","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.07.010","article-title":"Beyond mismatch repair deficiency? pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy","volume":"166","author":"Barrington","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"B114","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.10.007","article-title":"Macrophages in health and disease","volume":"185","author":"Park","year":"2022","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.4991","article-title":"Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and Monocytes1","volume":"164","author":"Bouchon","year":"2000","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1053\/j.gastro.2021.06.073","article-title":"Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a lynch syndrome mouse model","volume":"161","author":"Gebert","year":"2021","journal-title":"Gastroenterology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320946","article-title":"Naproxen chemoprevention promotes immune activation in lynch syndrome colorectal mucosa","volume":"70","author":"Reyes-Uribe","year":"2021","journal-title":"Gut"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23792","article-title":"Mutation of TGF\u03b2-RII eliminates NSAID cancer chemoprevention","volume":"9","author":"Mart\u00edn-L\u00f3pez","year":"2017","journal-title":"Oncotarget"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.410","article-title":"410 phase I interim study results of nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair\/microsatellite instability (dMMR\/MSI)","volume":"9","author":"Overman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3517","article-title":"A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I\/IIa clinical trial","volume":"26","author":"Kloor","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","article-title":"Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells","volume":"22","author":"Baharom","year":"2021","journal-title":"Nat Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210108","article-title":"Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN\u2013driven CCL5 and CXCL10","volume":"218","author":"Mowat","year":"2021","journal-title":"J Exp Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA Sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers"},{"key":"B126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"B129","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00002371-200107000-00005","article-title":"Dendritic cell\u2013dead cell interactions: implications and relevance for immunotherapy","volume":"24","author":"Fonteneau","year":"2001","journal-title":"J Immunother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000251","article-title":"DC Strategies for eliciting mutation-derived tumor antigen responses in patients","volume":"23","author":"Balan","year":"2017","journal-title":"Cancer J Sudbury Mass"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine\u2013induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_1092_20","article-title":"Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research","volume":"17","author":"Suto","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.898732","article-title":"Methods for establishing a renal cell carcinoma tumor spheroid model with immune infiltration for immunotherapeutic studies","volume":"12","author":"Lugand","year":"2022","journal-title":"Front Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1210164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T05:58:51Z","timestamp":1688968731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1210164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2023.1210164"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1210164","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"article-number":"1210164"}}